Integrative analysis of risk factors for immune-related adverse events of checkpoint blockade therapy in cancer
Changhwan Sung(Ulsan College), Sook Ryun Park(Ulsan College), Seyoung Seo(Ulsan College), Eun Joo Kang(Korea University), Min Hee Hong(Yonsei University), Shinkyo Yoon(Ulsan College), Ji‐Youn Han(National Cancer Centre Japan), Dae Ho Lee(Asan Medical Center), Il Hwan Kim(Louisiana State University), Jae‐Ho Jeong(Ulsan College), Chang‐Min Choi(Ulsan College), Jung Kyoon Choi(Korea Advanced Institute of Science and Technology), Jaesoon Park(Korea Advanced Institute of Science and Technology), Jae‐Lyun Lee(Ulsan College), Jinhyeon An(Korea Advanced Institute of Science and Technology), Jae Cheol Lee(Ulsan College), Sun‐Young Kong(National Cancer Center), Changhoon Yoo(Ulsan College), Sun Young Kim(Ulsan College), Jee Hyun Kim(Korea University), Tae-Yong Kim(Changwon National University), Soo Hyun Lee(Korea Advanced Institute of Science and Technology), Yeon Hee Park(Samsung Medical Center), Sang‐We Kim(Ulsan College), Kang Seon Lee(Korea Advanced Institute of Science and Technology)
Cited by 46
Related Papers
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
|New England Journal of Medicine|2017|3.4k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
Trastuzumab Deruxtecan in Previously Treated HER2-Low Advanced Breast Cancer
|New England Journal of Medicine|2022|2.5k
Osimertinib in Resected <i>EGFR</i> -Mutated Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|1.7k